Tevogen Bio Confirms Ongoing Efficacy Of TVGN 489 Against Dominant FLiRT Strains Of SARS-CoV-2
Portfolio Pulse from Benzinga Newsdesk
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced that its investigational immunotherapy, TVGN 489, remains effective against the dominant FLiRT strains of SARS-CoV-2. This therapy targets multiple SARS-CoV-2 proteins and retains 95% activity against these variants, including the current dominant strain, KP.2.
June 06, 2024 | 7:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tevogen Bio's TVGN 489 retains 95% efficacy against the dominant FLiRT strains of SARS-CoV-2, including the current dominant strain KP.2. This positive development could boost investor confidence in the company's stock.
The confirmation of TVGN 489's efficacy against the dominant FLiRT strains of SARS-CoV-2 is a significant positive development for Tevogen Bio. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100